J&J says Tremfya posts sustained Crohn’s remission through 3 years in Phase 3 GALAXI studies
JNJ•Johnson & Johnson said patients with moderate to severe Crohn’s disease maintained symptom control and intestinal healing through three years of Phase 3 GALAXI studies of Tremfya; results were slated for presentation at the American College of Gastroenterology’s 2026 annual meeting.
1. Three-year findings
Johnson & Johnson disclosed three-year Phase 3 data for Tremfya in moderate to severe Crohn’s disease, reporting that patients maintained symptom control and intestinal healing across both maintenance dosing regimens. The company said safety through three years matched Tremfya’s established profile in Crohn’s disease.
